Dr. Frantz Le Devedec
Frantz has over 15 years of experience in academic and industrial R&D projects, including material sciences and drug delivery formulations. He is author of over a dozen research papers and patents. His background is in biochemistry, with a PhD in applied polymer chemistry, and expertise in analytical and pharmaceutical sciences.
Dr. Carlos Maldonado
SVP Clinical Development
Dr. Carlos Enrique Maldonado Muete is a physician, pharmacologist and professor of pharmacology who contributes his experience in biotechnology, pharmacovigilance, clinical studies and knowledge of the medical community and regulatory authorities, as a local and international lecturer. Among other roles, he has participated in medical and regulatory issues related to the approval and commercialization of several new medicines. Dr. Muete has achieved results through his role as a former Medical Director of international pharmaceutical companies and as an external advisor.
SVP, Technical Operations
Roland is a Pharmacist with high expertise in regulatory affairs processes in INVIMA, DIGEMID, ANMAT, COFEPRIS and ANVISA, great experience applying the national and international GMP and GLP legislation for biologic and allopathic Medicines, Phytoterapeuthic and cosmetic products, having played the role as lead inspector in Latin America, Central America and Asia for more than 5 years, and working as a Latam RA Manager of a Indian-American company he knows well the legislation and market access details of Center America & Latam countries.
VP of Scientific Affairs
Samantha’s experience investigating human physiology and cellular biology has allowed her to develop sophisticated laboratory and project management skills that contribute to Avicanna’s competitive edge in the department of Research and Development. More specifically, Samantha has been published on several different occasions and has also lead various conferences and presentations related to plant gene manipulation and cloning. Samantha received a Master of Science degree in from the University of Guelph.
Senior Formulation Scientist
With extensive experience in formulation development, Pauric is currently working as a Postdoctoral Researcher in Dr. Christine Allen’s research team at the Leslie Dan Faculty of Pharmacy, University of Toronto. In his current role, Pauric leads the collaborative cannabinoid research that is conducted between Dr. Allen’s group and Avicanna’s scientific team. The main aim of this research is to design and evaluate novel cannabinoid-based therapies for a variety of indications. Pauric has attained his Ph.D. in Pharmaceutical Chemistry from the University of Limerick in Ireland and holds a bachelor's degree in Medicinal Chemistry and Chemical Biology from the University College Dublin.
Global Scientific Advisory Board
Dr. Humberto Reynales
International Scientific Advisory Board
An epidemiology with a PhD degree in science offers more than 15 years of experience in the pharmaceutical industry including his tenure at Merck & Co and his role as the executive director of Caimed a multinational CRO.
Dr. Mauricio Torres-Pradilla
Fundación Universitaria De Ciencias
Dr. Mauricio Torres Pradilla is a Dermatologist with a specialization in pediatric dermatology. He has been involved in research on Atopic Dermatitis, Psoriasis, Epidermolysis Bullosa and Hemangiomas in Europe and South America. Mauricio has several publications on these topics, individually and in collaboration. He is currently the Head of Dermatology at Fundación Universitaria de Ciencias de la Salud in Bogota, Colombia and is a Dermatologist at Debra Colombia, dividing his time among three major teaching hospitals and private practice.
Dr. Alejandro Berlin
Princess Margaret Cancer Center
Dr. Berlin trained in Chile, Israel and Canada, and currently works as a staff Clinician-Scientist Radiation Oncologist at the Princess Margaret Cancer Centre. His practice focuses in the characterization of malignancies with MRI and molecular imaging, and original applications of combinatorial approaches using systemic agents, stereotactic and MRI-guided ablative treatments. He is particularly interested in the design of innovative clinical trials, translational oncology, and genomic-based biomarker discovery, conveying his clinical and research expertise towards novel treatments for patients with cancer.
Dr. Daniel N. Sauder
John Hopkins School Of Medicine
Past chairman of the Department of Dermatology at the Johns Hopkins School of Medicine, Dr. Sauder is the former Chief of Dermatology at University of Toronto and the past Head of Dermatology at University Medical Centre of Princeton. An excellent addition to our extraordinary group of top-class scientists, Dr. Sauder’s research has focused on the molecular mechanism of the cutaneous (skin) immune response with an instrumental role in developing the field of cutaneous cytokine biology by identifying the role of certain immune system molecules, interleukins and cytokines, in inflammatory skin diseases and tumors. He is the past President of the Canadian Dermatology Association, past and founding President of the Canadian Society for Investigative Dermatology and currently practices general dermatology at the Toronto Dermatology Centre. Dr. Sauder has trained at McGill University School of Medicine in Montreal and McMaster University Medical School and completed his Dermatology training at the Cleveland Clinic and the National Institutes of Health.
Dr. Max Jones
University of Guelph
Dr. Jones is a tenured associate professor in the Department of Plant Agriculture at the University of Guelph with a fifteen-year research career that commenced with developing micropropagation techniques for the conservation and production of consistent and high-quality Echinacea. He has worked on an array of species including medicinal plants, food crops, and endangered species in areas ranging from micropropagation, field production, genetic selection, and ethnobotany. Dr. Jones’ brings with him a breadth of knowledge and experience in plant propagation, success with plant cell and tissue culture of difficult species and insights into plant development mechanisms. Bringing scientific rigor to Canada’s cannabis Industry, Dr. Jones has obtained one of the first Health Canada research licences for the cultivation of Cannabis in a university setting - where he actively develops biotechnological tools for conservation, propagation, and genetic improvement of the crop. He has attained his Ph.D. from the University of British Columbia and holds his M.Sc. from the University of Guelph.